CA3146591A1 - T-cell modulatory polypeptides and methods of use thereof - Google Patents

T-cell modulatory polypeptides and methods of use thereof Download PDF

Info

Publication number
CA3146591A1
CA3146591A1 CA3146591A CA3146591A CA3146591A1 CA 3146591 A1 CA3146591 A1 CA 3146591A1 CA 3146591 A CA3146591 A CA 3146591A CA 3146591 A CA3146591 A CA 3146591A CA 3146591 A1 CA3146591 A1 CA 3146591A1
Authority
CA
Canada
Prior art keywords
polypeptide
seq
amino acid
hla
tmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3146591A
Other languages
English (en)
French (fr)
Inventor
Ronald D. Seidel Iii
Rodolfo J. Chaparro
John F. Ross
Saso CEMERSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cue Biopharma Inc
Original Assignee
Cue Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cue Biopharma Inc filed Critical Cue Biopharma Inc
Publication of CA3146591A1 publication Critical patent/CA3146591A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA3146591A 2019-09-20 2020-09-17 T-cell modulatory polypeptides and methods of use thereof Pending CA3146591A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962903441P 2019-09-20 2019-09-20
US62/903,441 2019-09-20
US202062990693P 2020-03-17 2020-03-17
US62/990,693 2020-03-17
US202063048561P 2020-07-06 2020-07-06
US63/048,561 2020-07-06
PCT/US2020/051255 WO2021055594A1 (en) 2019-09-20 2020-09-17 T-cell modulatory polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3146591A1 true CA3146591A1 (en) 2021-03-25

Family

ID=74884186

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3146591A Pending CA3146591A1 (en) 2019-09-20 2020-09-17 T-cell modulatory polypeptides and methods of use thereof

Country Status (11)

Country Link
US (2) US20220143063A1 (enExample)
EP (1) EP4030897A4 (enExample)
JP (1) JP7756072B2 (enExample)
KR (1) KR20220066075A (enExample)
CN (1) CN114423284A (enExample)
AU (1) AU2020348373A1 (enExample)
CA (1) CA3146591A1 (enExample)
IL (1) IL290635A (enExample)
MX (1) MX2022003367A (enExample)
TW (1) TW202126683A (enExample)
WO (1) WO2021055594A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
WO2019051127A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2021087840A1 (zh) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 肿瘤免疫治疗多肽及其应用
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
US11058751B1 (en) * 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
WO2022140759A2 (en) * 2020-12-23 2022-06-30 Janssen Biotech, Inc. Neoantigen peptide mimics
EP4308143A4 (en) * 2021-03-19 2025-06-04 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
EP4504802A4 (en) * 2022-04-07 2026-03-25 Cue Biopharma Inc IMMUNE CELL BINDING POLYPEPTIDES
CN115820736B (zh) * 2022-12-08 2024-05-10 西南大学 家蚕丝胶蛋白Ser4在提高蚕丝性能中的应用及其方法
WO2024264007A2 (en) * 2023-06-23 2024-12-26 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
WO2024264004A2 (en) * 2023-06-23 2024-12-26 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
WO2026125765A1 (en) 2024-12-13 2026-06-18 Immunoscape Pte. Ltd. Combination therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6652932B2 (ja) * 2014-06-18 2020-02-26 アルバート アインシュタイン カレッジ オブ メディシン ｓｙｎＴａｃポリペプチド及びその使用
EP3286222A4 (en) 2015-03-23 2018-08-08 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
RU2018130525A (ru) * 2016-01-27 2020-02-27 Цсл Беринг Ленгнау Аг РЕКОМБИНАНТНЫЕ Fc-МУЛЬТИМЕРЫ IgG
CA3014458A1 (en) * 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2017151940A2 (en) * 2016-03-03 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
SG11201808552XA (en) * 2016-05-18 2018-10-30 Cue Biopharma Inc T-cell modulatory multimeric polypeptides and methods of use thereof
CN110325205B (zh) * 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) * 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240005989A (ko) * 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
WO2019051127A1 (en) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
WO2019139896A1 (en) * 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
KR20230009426A (ko) 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 암을 처치하기 위한 의약 조성물

Also Published As

Publication number Publication date
JP7756072B2 (ja) 2025-10-17
US20220143063A1 (en) 2022-05-12
EP4030897A4 (en) 2023-10-18
IL290635A (en) 2022-04-01
MX2022003367A (es) 2022-04-11
KR20220066075A (ko) 2022-05-23
WO2021055594A1 (en) 2021-03-25
EP4030897A1 (en) 2022-07-27
US20250120996A1 (en) 2025-04-17
CN114423284A (zh) 2022-04-29
JP2022548472A (ja) 2022-11-21
AU2020348373A1 (en) 2022-02-24
TW202126683A (zh) 2021-07-16

Similar Documents

Publication Publication Date Title
US20250120996A1 (en) T-cell modulatory polypeptides and methods of use thereof
JP7403703B2 (ja) 多量体ポリペプチド、ホモ二量体及び医薬組成物
TWI856047B (zh) 多聚體ｔ細胞調節多肽及其使用方法
US20240067700A1 (en) T-cell modulatory polypeptides and methods of use thereof
US20240376177A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
CN113286621A (zh) 多聚体t细胞调节多肽及其使用方法
JP2022522404A (ja) Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
US20230241192A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
US20260109958A1 (en) T-Cell Modulatory Polypeptides and Methods of Use Thereof
HK40060108A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
HK40060108B (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
HK40089384A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
EA049816B1 (ru) Модулирующие т-клетки мультимерные полипептиды и способы их применения
WO2024264004A2 (en) T-cell modulatory polypeptides and methods of use thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240822

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240822

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240822

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240909

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240909

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240909

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241003

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241206

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241206

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250422

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250612

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250919

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260318

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260519